Modulators of alternative splicing as novel therapeutics in cancer

World Journal of Clinical Oncology

Volumn 6, Issue 5, 2015, Pages 92-95

  Oltean, Sebastian ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Alternative splicing; Novel cancer therapeutics; Small molecules; Splicing modulators; Splicing switching oligonucleotides

Indexed keywords

EID: 84945127144     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v6.i5.92     Document Type: Review

References (28)

1. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-3096 [PMID: 21383288 DOI: 10.1200/ JCO.2010.33.2312]
2. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-39 [PMID: 24382387 DOI: 10.1172/JCI69738]
3. Dietlein F, Thelen L, Reinhardt HC. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. Trends Genet 2014; 30: 326-339 [PMID: 25017190 DOI: 10.1016/j.tig.2014.06.003]
4. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011; 18: 1121-1126 [PMID: 21633392 DOI: 10.1038/gt.2011.79]
5. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005; 6: 386-398 [PMID: 15956978 DOI: 10.1038/nrm1645]
6. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by highthroughput sequencing. Nat Genet 2008; 40: 1413-1415 [PMID: 18978789 DOI: 10.1038/ng.259]
7. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476 [PMID: 18978772 DOI: 10.1038/nature07509]
8. Wang J, Zhang J, Li K, Zhao W, Cui Q. SpliceDisease database: linking RNA splicing and disease. Nucleic Acids Res 2012; 40: D1055-D1059 [PMID: 22139928]
9. Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene 2014; 33: 5311-5318 [PMID: 24336324 DOI: 10.1038/ onc.2013.533]
10. Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, Ling KK, Karp GM, Qi H, Woll MG, Chen G, Zhang N, Gabbeta V, Vazirani P, Bhattacharyya A, Furia B, Risher N, Sheedy J, Kong R, Ma J, Turpoff A, Lee CS, Zhang X, Moon YC, Trifillis P, Welch EM, Colacino JM, Babiak J, Almstead NG, Peltz SW, Eng LA, Chen KS, Mull JL, Lynes MS, Rubin LL, Fontoura P, Santarelli L, Haehnke D, McCarthy KD, Schmucki R, Ebeling M, Sivaramakrishnan M, Ko CP, Paushkin SV, Ratni H, Gerlach I, Ghosh A, Metzger F. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 2014; 345: 688-693 [PMID: 25104390 DOI: 10.1126/science.1250127]
11. Le Bacquer O, Shu L, Marchand M, Neve B, Paroni F, Kerr Conte J, Pattou F, Froguel P, Maedler K. TCF7L2 splice variants have distinct effects on beta-cell turnover and function. Hum Mol Genet 2011; 20: 1906-1915 [PMID: 21357677 DOI: 10.1093/hmg/ddr072]
12. Guo W, Schafer S, Greaser ML, Radke MH, Liss M, Govindarajan T, Maatz H, Schulz H, Li S, Parrish AM, Dauksaite V, Vakeel P, Klaassen S, Gerull B, Thierfelder L, Regitz-Zagrosek V, Hacker TA, Saupe KW, Dec GW, Ellinor PT, MacRae CA, Spallek B, Fischer R, Perrot A, Özcelik C, Saar K, Hubner N, Gotthardt M. RBM20, a gene for hereditary cardiomyopathy, regulates titin splicing. Nat Med 2012; 18: 766-773 [PMID: 22466703 DOI: 10.1038/nm.2693]
13. Biamonti G, Catillo M, Pignataro D, Montecucco A, Ghigna C. The alternative splicing side of cancer. Semin Cell Dev Biol 2014; 32: 30-36 [PMID: 24657195 DOI: 10.1016/j.semcdb.2014.03.016]
14. Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene 2015; 34: 1-14 [PMID: 24441040 DOI: 10.1038/onc.2013.570]
15. Wang H, Zhou M, Shi B, Zhang Q, Jiang H, Sun Y, Liu J, Zhou K, Yao M, Gu J, Yang S, Mao Y, Li Z. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 2011; 13: 461-471 [PMID: 21532887 DOI: 10.1593/neo.101744]
16. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al- Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009; 219: 435-445 [PMID: 19824059 DOI: 10.1002/path.2625]
17. Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC. Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Differ 2014; 21: 1377-1387 [PMID: 24926616 DOI: 10.1038/ cdd.2014.73]
18. Zhang K, Nowak I, Rushlow D, Gallie BL, Lohmann DR. Patterns of missplicing caused by RB1 gene mutations in patients with retinoblastoma and association with phenotypic expression. Hum Mutat 2008; 29: 475-484 [PMID: 18181215 DOI: 10.1002/ humu.20664]
19. Lohmann DR. RB1 gene mutations in retinoblastoma. Hum Mutat 1999; 14: 283-288 [PMID: 10502774 DOI: 10.1002/(SICI)1098-10 04(199910)14: 4<283: : AID-HUMU2>3.0.CO; 2-J]
20. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-1395 [PMID: 21995386 DOI: 10.1056/ NEJMoa1103283]
21. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8: 880-887 [PMID: 18923433 DOI: 10.1038/nrc2505]
22. Eblen ST. Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol 2012; 83: 1063-1072 [PMID: 22248731 DOI: 10.1016/j.bcp.2011.12.041]
23. Salton M, Kasprzak WK, Voss T, Shapiro BA, Poulikakos PI, Misteli T. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun 2015; 6: 7103 [PMID: 25971842 DOI: 10.1038/ncomms8103]
24. Singh RK, Cooper TA. Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 2012; 18: 472-482 [PMID: 22819011 DOI: 10.1016/j.molmed.2012.06.006]
25. Ding Y, Zhang H, Zhou Z, Zhong M, Chen Q, Wang X, Zhu Z. u-PA inhibitor amiloride suppresses peritoneal metastasis in gastric cancer. World J Surg Oncol 2012; 10: 270 [PMID: 23234499 DOI: 10.1186/1477-7819-10-270]
26. Gammons MV, Fedorov O, Ivison D, Du C, Clark T, Hopkins C, Hagiwara M, Dick AD, Cox R, Harper SJ, Hancox JC, Knapp S, Bates DO. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest Ophthalmol Vis Sci 2013; 54: 6052-6062 [PMID: 23887803]
27. Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer 2014; 111: 477-485 [PMID: 25010863 DOI: 10.1038/bjc.2014.342]
28. Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene 2015; 34: 4311-4319 [PMID: 25381816]